BriaCell Subsidiary BriaPro Secures $3M Credit Facility and sCD80 License from Parent

summarizeSummary

BriaCell Therapeutics Corp. announced that its subsidiary, BriaPro Therapeutics Corp., secured a $3 million credit facility and an exclusive sCD80 cancer treatment license from BriaCell, with BriaCell increasing its ownership in BriaPro to 78%.

check_boxKey Events

• Subsidiary BriaPro Receives $3M Credit Facility

  BriaCell Therapeutics Corp. has agreed to provide its subsidiary, BriaPro Therapeutics Corp., a credit facility of up to $3,000,000 to fund research and development activities for sCD80, addressing BriaPro's critical liquidity needs.

• BriaPro Acquires sCD80 Cancer Treatment License

  BriaPro Therapeutics Corp. acquired an exclusive worldwide license from BriaCell to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for cancer treatment, expanding its pipeline.

• BriaCell Increases Ownership in BriaPro

  As consideration for the license and credit facility, BriaPro issued 23,972,589 common shares to BriaCell, valued at approximately C$1.18 million, increasing BriaCell's ownership interest in BriaPro to approximately 78%.

• BriaPro Reports Going Concern Warning

  BriaPro Therapeutics Corp.'s unaudited financial statements for the period ended January 31, 2026, include a going concern warning, citing accumulated losses of $1.65 million and dependence on BriaCell for financing.

auto_awesomeAnalysis

This 8-K filing by BriaCell Therapeutics Corp. discloses significant inter-company transactions that address the going concern warning of its subsidiary, BriaPro Therapeutics Corp. BriaPro, which reported a $1 cash balance and a negative working capital of $1.64 million, is acquiring an exclusive license to develop and commercialize Soluble CD80 (sCD80) for cancer treatment from BriaCell. Crucially, BriaCell is providing a credit facility of up to $3 million to BriaPro to fund sCD80 R&D, effectively providing a lifeline to the cash-strapped subsidiary. In return, BriaPro issued 23,972,589 common shares to BriaCell, valued at approximately C$1.18 million (approximately $0.86 million USD), increasing BriaCell's ownership in BriaPro to about 78%. This transaction, which closed on March 30, 2026, also saw Jamieson Bondarenko, Chairman of BriaCell, appointed Chairman of BriaPro's board, strengthening strategic alignment. The substantial capital commitment and asset transfer are critical for BriaPro's continued operations and pipeline development, and represent a material strategic investment for BriaCell.